A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease ; volume:38 ; number:7 ; day:5 ; month:6 ; year:2024 ; pages:493-505 ; date:7.2024
CNS drugs ; 38, Heft 7 (5.6.2024), 493-505, 7.2024
- Creator
-
Rosenbloom, Michael H.
O’Donohue, Tricia
Zhou-Clark, Domi
Mala, Deepashni
Frazier, Andrew
Tarrant, Michael
Modrijan, Michelle
Riveira, Melora
Chapman, Darla
Griffin, Yvonne
Shakalis, Lauren
Grabowski, Thomas J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-024-01097-w
- URN
-
urn:nbn:de:101:1-2408271259090.909865978591
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rosenbloom, Michael H.
- O’Donohue, Tricia
- Zhou-Clark, Domi
- Mala, Deepashni
- Frazier, Andrew
- Tarrant, Michael
- Modrijan, Michelle
- Riveira, Melora
- Chapman, Darla
- Griffin, Yvonne
- Shakalis, Lauren
- Grabowski, Thomas J.
- SpringerLink (Online service)
Other Objects (12)
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
Treatments in Alzheimer’s disease
New treatments in Alzheimer’s disease
Automated detection of early-stage Alzheimer’s Disease
Amyloid antibody therapy for early-stage Alzheimer’s disease: a critical review of three recent trials
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Disease-modifying treatments in Alzheimer’s disease
Amyloid PET imaging: applications beyond Alzheimer’s disease
New approaches to symptomatic treatments for Alzheimer’s disease
Blood Derived Amyloid Biomarkers for Alzheimer’s Disease Prevention
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
Treatments in Alzheimer’s disease
New treatments in Alzheimer’s disease
Automated detection of early-stage Alzheimer’s Disease
Amyloid antibody therapy for early-stage Alzheimer’s disease: a critical review of three recent trials
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Disease-modifying treatments in Alzheimer’s disease
Amyloid PET imaging: applications beyond Alzheimer’s disease
New approaches to symptomatic treatments for Alzheimer’s disease
Blood Derived Amyloid Biomarkers for Alzheimer’s Disease Prevention
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
Treatments in Alzheimer’s disease
New treatments in Alzheimer’s disease
Automated detection of early-stage Alzheimer’s Disease
Amyloid antibody therapy for early-stage Alzheimer’s disease: a critical review of three recent trials
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Disease-modifying treatments in Alzheimer’s disease
Amyloid PET imaging: applications beyond Alzheimer’s disease
New approaches to symptomatic treatments for Alzheimer’s disease